REGENXBIO to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) announced its presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 11:40 a.m. ET. This virtual conference will showcase the company's advancements in gene therapy. A webcast will be available on REGENXBIO's website, with an archived replay accessible for 30 days. The company utilizes its proprietary NAV Technology Platform to develop innovative gene delivery systems across multiple therapeutic areas.

ROCKVILLE, Md., Jan. 11, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39^th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET. The conference will be held in a virtual meeting format.

A webcast of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com

Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

View original content:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301203628.html

SOURCE REGENXBIO Inc.

FAQ

What will REGENXBIO present at the J.P. Morgan Healthcare Conference?

REGENXBIO will present advancements in gene therapy at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021.

When is the REGENXBIO presentation scheduled?

The presentation is scheduled for January 14, 2021, at 11:40 a.m. ET.

How can I access the REGENXBIO presentation?

The presentation can be accessed via a webcast on REGENXBIO's website, with a replay available for 30 days.

What is the focus of REGENXBIO's gene therapy?

REGENXBIO focuses on developing gene therapies using its NAV Technology Platform, which utilizes more than 100 novel AAV vectors.

What is the stock symbol for REGENXBIO?

The stock symbol for REGENXBIO is RGNX.